ArticleVaccines2026
Structure-Dependent Innate Immune Compatibility of Sup35 G7-Derived Self-Assembling Peptide Nanomaterials in an Immune-Compatibility Assessment.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveSelf-assembling peptide nanomaterials are increasingly investigated as modular platforms for vaccine delivery and immune modulation. However, their structure-dependent interactions with immune cells remain insufficiently defined, limiting their early evaluation as peptide nanomaterial. This study evaluated the physicochemical properties and immunological effects of three Sup35 G7-derived self-assembling peptide nanomaterials, G7, G7d, and G7d(PEG)HER2, with particular attention to innate immune compatibility and macrophage responses.
methodsThe morphology and surface charge of the peptides were characterized by transmission electron microscopy and zeta-potential analysis. Their cytocompatibility was assessed in THP-1 macrophages, Jurkat T cells, and IM-9 B cells. Transcriptomic and proteomic analyses were integrated to identify immune-cell-specific molecular responses. Cellular uptake, apoptosis, cytokine secretion, and intracellular reactive oxygen species production were further examined in macrophages. In vivo immunization in BALB/c mice was conducted to assess systemic immunoglobulin responses.
resultsG7 and G7d assembled into large crystalline aggregates with limited dispersibility, whereas PEGylated G7d(PEG)HER2 formed more uniform nanofibers. All three materials showed positive zeta potentials and relatively low cytotoxicity across the tested immune cell models. Among these cells, macrophages displayed the strongest molecular responses. Integrated transcriptomic and proteomic analyses revealed coordinated alterations mainly involving metabolic remodeling, redox homeostasis, proteasome activity, and mitochondrial-associated pathways, rather than predominant activation of classical pro-inflammatory signaling. Ultrastructural analysis confirmed intracellular uptake of assembled peptides and mitochondrial morphological changes without detectable apoptosis. Cytokine profiling showed reduced secretion of multiple cytokines and chemokines, while G7 induced higher intracellular reactive oxygen species than G7d and G7d(PEG)HER2. In vivo, G7d administration was associated with increased serum IgG levels, whereas G7 showed a moderate effect and G7d(PEG)HER2 exhibited minimal changes; IgM levels remained unchanged.
conclusionsSup35 G7 based self-assembling peptides exhibit low acute toxicity but induce structure-dependent modulation of macrophage function. Differences in assembly morphology and surface modification may influence systemic humoral responses. These findings support the importance of physicochemical design in evaluating immune compatibility of peptide nanomaterial scaffolds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.